HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lebtahi, R. Articles by Le Guludec, D. Search for Related Content PubMed PubMed Citation Articles by Lebtahi, R. Articles by Le Guludec, D.

Detection of Neuroendocrine Tumors: ^99mTc-P829 Scintigraphy Compared with ¹¹¹In-Pentetreotide Scintigraphy

¹ Nuclear Medicine Department, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
² Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France
³ Nuclear Medicine Department, Hôpital Universitaire Neuro-Cardiologique, Lyon, France
⁴ Gastroenterology Department, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France

The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, ^99mTc-P829, compared with that of ¹¹¹In-pentetreotide. Methods: Forty-three patients (32 men, 11 women; age range, 24–78 y; mean age, 56 y) with biologically or histologically proven neuroendocrine tumors were prospectively included: 11 patients with Zollinger-Ellison syndrome, 16 patients with carcinoid tumors, and 16 patients with other types of functioning (n = 6) or nonfunctioning (n = 10) endocrine tumors. ¹¹¹In-Pentetreotide planar images (head, chest, abdomen, and pelvis) were obtained 4 and 24 h after injection of 10 µg somatostatin analog labeled with 148 ± 17 MBq ¹¹¹In, and SPECT was performed 24 h after injection. Similar ^99mTc-P829 planar images were obtained at 1, 4–6, and 24 h after injection of 50 µg peptide labeled with 991.6 ± 187.59 MBq ^99mTc. Abdominal SPECT was performed 4–6 h after injection. Results: ¹¹¹In-Pentetreotide detected 203 tumoral sites in 39 (91%) of 43 patients, whereas ^99mTc-P829 detected 77 sites in 28 (65%) of 43 patients (P < 0.005). In the liver, 129 sites (in 24 patients) were detected by ¹¹¹In-pentetreotide scintigraphy and 34 sites (in 10 patients) were detected by ^99mTc-P829 scintigraphy. Conclusion: In patients with endocrine tumors, the detection rate of ^99mTc-P829 scintigraphy was lower than that of ¹¹¹In-pentetreotide scintigraphy, which appeared to be more sensitive, especially for liver metastases.

Key Words: somatostatin receptor scintigraphy • ^99mTc-P829 scintigraphy • endocrine tumors

This article has been cited by other articles:

				D. J Kwekkeboom, B. L Kam, M. van Essen, J. J M Teunissen, C. H J van Eijck, R. Valkema, M. de Jong, W. W de Herder, and E. P Krenning Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors Endocr. Relat. Cancer, January 29, 2010; 17(1): R53 - R73. [Abstract] [Full Text] [PDF]

				S Scigliano, R Lebtahi, F Maire, J L Stievenart, R Kianmanesh, A Sauvanet, M P Vullierme, A Couvelard, J Belghiti, P Ruszniewski, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience Endocr. Relat. Cancer, September 1, 2009; 16(3): 977 - 990. [Abstract] [Full Text] [PDF]

				M. Rodrigues, S. Li, M. Gabriel, D. Heute, M. Greifeneder, and I. Virgolini 99mTc-Depreotide Scintigraphy Versus 18F-FDG-PET in the Diagnosis of Radioiodine-Negative Thyroid Cancer J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3997 - 4000. [Abstract] [Full Text] [PDF]

				D. Storch, M. Behe, M. A. Walter, J. Chen, P. Powell, R. Mikolajczak, and H. R. Macke Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization? J. Nucl. Med., September 1, 2005; 46(9): 1561 - 1569. [Abstract] [Full Text] [PDF]

				M. Ginj, J. Chen, M. A. Walter, V. Eltschinger, J. C. Reubi, and H. R. Maecke Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy Clin. Cancer Res., February 1, 2005; 11(3): 1136 - 1145. [Abstract] [Full Text] [PDF]

				B. Van Den Bossche and C. Van de Wiele Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				M. Gabriel, C. Decristoforo, E. Donnemiller, H. Ulmer, C. Watfah Rychlinski, S. J. Mather, and R. Moncayo An Intrapatient Comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-Octreotide for Diagnosis of Somatostatin Receptor-Expressing Tumors J. Nucl. Med., May 1, 2003; 44(5): 708 - 716. [Abstract] [Full Text] [PDF]